Search Result

Results for "

glucose tolerance mice

" in MedChemExpress (MCE) Product Catalog:

By Targets:	SGLT (1) 11β-HSD (1) 5-HT Receptor (3) AMPK (4) Apoptosis (4) Bacterial (1) Cannabinoid Receptor (1) Casein Kinase (1) Drug Derivative (1) Endogenous Metabolite (2) FBPase (2) Free Fatty Acid Receptor (2) G protein-coupled Bile Acid Receptor 1 (2) GLP Receptor (2) Glucokinase (1) Glycosidase (3) GPR119 (5) HIF/HIF Prolyl-Hydroxylase (1) IDE (1) IKK (1) Insulin Receptor (1) Interleukin Related (1) JNK (1) mTOR (1) NF-κB (4) NO Synthase (1) Olfactory Receptor (1) Orphan GPCR (1) p38 MAPK (2) PDHK (1) PGC-1α (1) Phosphoglycerate Dehydrogenase (PHGDH) (1) Phospholipase (2) PPAR (1) Ras (3) Reference Standards (2) Ribosomal S6 Kinase (RSK) (1) Somatostatin Receptor (2) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (6) Infection (1) Inflammation/Immunology (6) Metabolic Disease (35) Neurological Disease (4)

By Targets:

SGLT (1)

11β-HSD (1)

5-HT Receptor (3)

AMPK (4)

Apoptosis (4)

Bacterial (1)

Cannabinoid Receptor (1)

Casein Kinase (1)

Drug Derivative (1)

Endogenous Metabolite (2)

FBPase (2)

Free Fatty Acid Receptor (2)

G protein-coupled Bile Acid Receptor 1 (2)

GLP Receptor (2)

Glucokinase (1)

Glycosidase (3)

GPR119 (5)

HIF/HIF Prolyl-Hydroxylase (1)

IDE (1)

IKK (1)

Insulin Receptor (1)

Interleukin Related (1)

JNK (1)

mTOR (1)

NF-κB (4)

NO Synthase (1)

Olfactory Receptor (1)

Orphan GPCR (1)

p38 MAPK (2)

PDHK (1)

PGC-1α (1)

Phosphoglycerate Dehydrogenase (PHGDH) (1)

Phospholipase (2)

PPAR (1)

Ras (3)

Reference Standards (2)

Ribosomal S6 Kinase (RSK) (1)

Somatostatin Receptor (2)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (6)

Cardiovascular Disease (6)

Infection (1)

Inflammation/Immunology (6)

Metabolic Disease (35)

Neurological Disease (4)

Inhibitors & Agonists

Peptides

Natural
Products

Targets Recommended: GLUT Glucose-6-Phosphate Isomerase (GPI) SGLT

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101966

NCT-503 25+ Cited Publications	Phosphoglycerate Dehydrogenase (PHGDH)	Metabolic Disease Cancer
NCT-503 is a blood-brain barrier-permeable, non-competitive PHGDH inhibitor with an IC₅₀ of 2.5 μM against human PHGDH. NCT-503 reduces glucose-derived serine production and the incorporation of one-carbon units into nucleotides without decreasing PHGDH protein expression. NCT-503 prevents high selenium-induced insulin resistance in mice by regulating blood glucose and insulin levels and improving glucose tolerance, and also inhibits the growth of tumors overexpressing PHGDH. NCT-503 can be used in research related to insulin resistance and breast cancer .

HY-N8518

Malabaricone C 3 Publications Verification	Phospholipase p38 MAPK Apoptosis NF-κB	Metabolic Disease Inflammation/Immunology Cancer
Malabaricone C is an orally active and noncompetitive sphingomyelin synthase (SMS) inhibitor with IC₅₀ values of 3 μM and 1.5 μM for SMS 1 and SMS 2, respectively. Malabaricone C reduces body weight gain, improves glucose tolerance, and decreases lipid accumulation in the liver, showing significant prevention of high fat diet-induced fatty liver in mice. Malabaricone C has anti-inflammatory effects, which is found in the fruits of Myristica cinnamomea King. Malabaricone C is promising for research of obesity and immunological disorders caused due to hyper-activation of T-cells .

HY-13991

CCG-1423 10+ Cited Publications	Ras Apoptosis	Cancer
CCG-1423 is an inhibitor of Rho/MRTF/SRF pathway. CCG-1423 shows activities in several cancer cells. CCG-1423 is a promising lead compound for the development of novel pharmacologic tools, and it can be used for the research of cancer and diabetes .

HY-N15721

Tryptophan-cholic acid Trp-CA	Orphan GPCR GLP Receptor	Metabolic Disease
Tryptophan-cholic acid (Trp-CA) is a microbial amino acid-conjugated bile acid that acts as an endogenous ligand and agonist (EC₅₀=9.6 μM) for the orphan G protein-coupled receptor (GPCR) MRGPRE (Mas-related G protein-coupled receptor family member E). Tryptophan-cholic acid is orally effective but has poor oral absorption and does not cross the blood-brain barrier. Tryptophan-cholic acid promotes the secretion of glucagon-like peptide GLP-1, thereby improving glucose tolerance in diabetic mice. Tryptophan-cholic acid improves glucose tolerance, promotes insulin secretion, and alleviates high-fat diet-induced hepatic steatosis without causing pruritus side effects. Tryptophan-cholic acid is primarily used in research on type 2 diabetes (T2D) .

HY-12443

PF-5006739	Casein Kinase	Neurological Disease
PF-5006739 is a potent and selective inhibitor of CK1δ/ε with IC₅₀s of 3.9 nM and 17.0 nM, respectively. PF-5006739 is a potential therapeutic agent for a range of psychiatric disorders with low nanomolar in vitro potency for CK1δ/ε and high kinome selectivity. PF-5006739 attenuats opioid agent-seeking behavior in a rodent operant reinstatement model in animals in a dose-dependent manner . PF-5006739 improves glucose tolerance in both diet-induced obesity (DIO) and genetic (ob/ob) mice models of obesity .

HY-123297

TUG-469	Free Fatty Acid Receptor	Metabolic Disease
TUG-469 is a selective free fatty acid receptor 1 (FFA1/GPR40) agonist with an EC₅₀ value of 19 nM. TUG-469 is >200-fold selective for FFA1 over FFA4. TUG-469 significantly improves glucose tolerance in pre-diabetic mice. TUG-469 can be used for the research of diabetes .

HY-N7515

Pinocembrin chalcone 2',4',6'-Trihydroxychalcone	Bacterial AMPK	Infection Metabolic Disease Inflammation/Immunology
Pinocembrin chalcone (2',4',6'-Trihydroxychalcone) is an antibacterial compound from Helichrysum Trilineatum. Pinocembrin chalcone facilitates AMP-activated protein kinase (AMPK) activation, improves glucose tolerance, increases muscle FAO and reduces fat accumulation in the liver and skeletal muscles in high-fat diet-induced (HFD) diabetic mice. Pinocembrin chalcone is promising for research of gastric ulcers and diabetes .

HY-P1434

[Pro3]-GIP (mouse)	Insulin Receptor	Metabolic Disease
[Pro3]-GIP (mouse) is a GIP receptor antagonist (IC₅₀: 2.6 μM). [Pro3]-GIP (mouse) improves glucose tolerance and insulin sensitivity in ob/ob mice. [Pro3]-GIP (mouse) can be used for research of type 2 diabetes .

HY-120565

WB403	G protein-coupled Bile Acid Receptor 1	Metabolic Disease
WB403 is an orally active TGR5 activator with an EC₅₀ of 5.5 μM against human TGR5. WB403 activates TGR5 to stimulate downstream signaling pathways, promote GLP-1 secretion, improve glucose tolerance in mice with type 2 diabetes, and reduce levels of fasting blood glucose, postprandial blood glucose and HbA1c. WB403 increases pancreatic β-cell mass and restores the distribution of α-cells and β-cells in islets. WB403 is applicable to the research of type 2 diabetes .

HY-N8522

9,10-Dihydroxystearic acid	Others	Metabolic Disease
9,10-Dihydroxystearic acid is an oxidation product of oleic acid. 9,10-Dihydroxystearic acid can improve glucose tolerance and insulin sensitivity in KKAy mice .

HY-111254

GQ-16	PPAR NF-κB JNK	Inflammation/Immunology
GQ-16 is an orally active PPARγ partial agonist with an IC₅₀ of 1.84 μM and a K_i of 160 nM against human PPARγ. GQ-16 inhibits Cdk5-mediated Ser-273 phosphorylation. GQ-16 improves insulin sensitivity and glucose tolerance in obese and diabetic mice. GQ-16 also exhibits certain cytotoxicity against tumor cells. GQ-16 can be used in research related to obesity, diabetes and cancer .

HY-128578

KPLH1130 2 Publications Verification	PDHK NO Synthase Interleukin Related HIF/HIF Prolyl-Hydroxylase	Metabolic Disease Inflammation/Immunology
KPLH1130 is a pyruvate dehydrogenase kinase (PDK) inhibitor. KPLH1130 potently inhibits M1 macrophage polarization by reducing the expression of pro-inflammatory cytokines, decreasing the levels of M1 phenotype markers (HIF-1α, iNOS) and nitric oxide (NO) production. KPLH1130 prevents the reduction of mitochondrial oxygen consumption rate (OCR) induced by inflammatory stimuli (LPS ((HY-D1056) + IFN-γ) in various macrophage types. KPLH1130 improves glucose tolerance in HFD-fed mice. KPLH1130 can be used for the study of obesity-associated metabolic disorders and other inflammatory conditions .

HY-155157

PF-07247685	Endogenous Metabolite	Cardiovascular Disease
PF-07247685 is a BCKDC kinase (BDK) inhibitor (EC₅₀=2.2 nM). PF-07247685 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07247685 improved cardiometabolic endpoints and improves glucose tolerance in mice .

HY-131334

AMPK activator 4	AMPK	Metabolic Disease
AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect .

HY-17538A

ZLN005 hydrochloride	PGC-1α	Metabolic Disease
ZLN005 (hydrochloride) is a peroxisome proliferator-activated receptor-g coactivator-1a (PGC-1α) activator. ZLN005 (hydrochloride) can stimulate the expression of PGC-1α and downstream genes in skeletal muscle cells, improve glucose utilization and fatty acid oxidation. ZLN005 (hydrochloride) can increase the transcription of PGC-1α and downstream genes in skeletal muscle of diabetic db/db mice, increase fat oxidation and improve glucose tolerance, pyruvate tolerance and insulin sensitivity .

HY-177297

LCZ960 NVP-LCZ960	Glucokinase	Metabolic Disease
LCZ960 is an orally active glucokinase (GK) activator. LCZ960 stimulates GK activity in hepatocytes in vitro and stimulates glucose uptake in vivo through hepatic GK activation. LCZ960 lowers blood glucose in mice with diet-induced obesity (DIO). LCZ960 maintains normoglycemia and improves glucose tolerance in DIO mice and rats. LCZ960 stimulates glycogen synthase flux and increases hepatic glycogen turnover in rats. LCZ960 induces increased hepatic glycogen recycling. LCZ960 can be used to study high-fat diet-induced obesity and type 2 diabetes .

HY-178857

CB1 antagonist 6	Cannabinoid Receptor	Metabolic Disease
CB1 antagonist 6 (Compound 11jE2) is an orally active CB1R antagonist, with an IC₅₀ value of 23 nM. CB1 antagonist 6 significantly reduces food intake and body weight, improves glucose tolerance and insulin resistance, and decreases serum ALT and AST levels in diet-induced obese (DIO) mice, demonstrating hepatoprotective effects. CB1 antagonist 6 can be used for the study of metabolic syndrome (obesity, diabetes) .

HY-186028

HOR1-C59	Olfactory Receptor	Metabolic Disease
HOR1-C59 is a highly selective Or5v1/Olfr110 agonist with an EC₅₀ of 7.12 nM. HOR1-C59 can improve glucose homeostasis, alleviate obesity and insulin resistance. HOR1-C59 is applicable for obesity-related research .

HY-161281

α-Glucosidase-IN-49	Glycosidase	Metabolic Disease
α-Glucosidase-IN-49 (compound C23) is a potent inhibitor of α-Glucosidase, with IC₅₀ of 0.52 μM. α-Glucosidase-IN-49 has oral bioactivity that can reduce blood glucose and improve glucose tolerance in mice .

HY-155156

PF-07238025	Endogenous Metabolite	Cardiovascular Disease
PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC₅₀=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice .

HY-U00134

Benzcyclane Bencyclane; Benzcyclan	5-HT Receptor	Cardiovascular Disease Neurological Disease
Benzcyclane (Bencyclane; Benzcyclan) is a serotonin receptor antagonist and a cerebral/peripheral vasodilator. Benzcyclane exerts atypical serotonin antagonistic effects in rabbit superior mesenteric arteries. Benzcyclane relaxes high K ⁺-induced contractions in rabbit basilar arteries and superior mesenteric arteries, and selectively inhibits sympathetic nerve stimulation-induced contractions in rabbit pulmonary arteries. Benzcyclane exerts non-competitive norepinephrine antagonistic effects in rabbit superior mesenteric arteries, and slightly reduces the maximum contractile response induced by histamine. Benzcyclane relaxes smooth muscles, induces transient hypotension, inhibits thrombosis, and accelerates blood fibrinolytic activity. Benzcyclane increases cerebral glucose content/uptake, enhances hypoxia tolerance in mice, and increases cerebral blood supply in dogs. Benzcyclane is applicable to studies related to cerebral vascular circulation .

HY-173479

GLP-1R agonist 30	GLP Receptor	Cardiovascular Disease Metabolic Disease
GLP-1R agonist 30 is a selective and orally active GLP-1R agonist with an EC₅₀ of 0.048 nM. GLP-1R has excellent selectivity, with EC₅₀ greater than 20 μM for GLP-2R, GIPR, and GCPR. GLP-1R agonist significantly increases cAMP-stimulating activity while markedly reducing hERG inhibitory activities. GLP-1R agonist has preferable absorption and excellent β-arrestin pathway selectivity. GLP-1R agonist effectively improves glucose tolerance and promoted insulin secretion in B-hGLP1R knock-in mice .

HY-162893

SX29	Glycosidase	Metabolic Disease
SX29 is an orally active non-competitive α-glucosidase inhibitor with an IC₅₀ value of 2.12 μM. SX29 exhibits hypoglycemic activity, and oral administration of SX29 can reduce blood glucose levels and improve glucose tolerance in diabetic mice .

HY-117446

AS-1669058	GPR119	Metabolic Disease
AS-1669058 is a GPR119 agonist and a potential inhibitor of type 2 diabetes. AS-1669058 induces insulin secretion in response to high blood glucose levels in vitro and in vivo and increases insulin promoter activity. In animal studies, AS-1669058 improved glucose tolerance and reduced blood glucose levels in db/db mice .

HY-117446A

AS-1669058 free base	GPR119	Metabolic Disease
AS-1669058 free base is a GPR119 agonist and a potential inhibitor of type 2 diabetes. AS-1669058 free base induces insulin secretion induced by high blood glucose levels in vitro and in vivo and increases insulin promoter activity. In animal studies, AS-1669058 free base improved glucose tolerance and reduced blood glucose levels in db/db mice.

HY-155553

GPR119 agonist 2	GPR119	Metabolic Disease
GPR119 agonist 2 (compound 43) is an orally active GPR119 agonist. GPR119 agonist 2 shows good pharmacokinetic characteristics in rodents and can effectively improve glucose tolerance in mice and rats. GPR119 agonist 2 has the potential to study type 2 diabetes .

HY-133180

YW1128	Wnt β-catenin	Metabolic Disease
YW1128 (compound 3a) is a potent Wnt/β-Catenin inhibitor. YW1128 induces the proteasome degradation of β-catenin and subsequent inhibits the Wnt/β-catenin signaling in cells. YW1128 significantly decreases hepatic lipid accumulation. YW1128 improves glucose tolerance of high fat diet-fed mice without noticeable toxicity. YW1128 down regulates the genes involved in the glucose and fatty acid anabolism .

HY-125327

YM-543	SGLT	Metabolic Disease
YM-543 is a selective SGLT2 inhibitor that effectively reduces hyperglycemia in type 2 diabetic mice through increased urinary glucose excretion. YM-543 demonstrates potent inhibition of both mouse and human SGLT2 activities at nanomolar concentrations. YM-543, when administered orally, significantly improves glucose tolerance in diabetic models and sustains its effects for over 12 hours. YM-543, in combination with other antidiabetic agents like rosiglitazone or metformin, enhances the therapeutic effects on diabetic symptoms. YM-543 does not affect blood glucose levels in normal mice, indicating its specificity for diabetic conditions.

HY-147678

GPR40 agonist 5	Free Fatty Acid Receptor	Metabolic Disease
GPR40 agonist 5 (compound I-14) is an orally active and potent GPR40 (G protein coupled receptor 40) agonist, with an EC₅₀ of 47 nM. GPR40 agonist 5 decreases the levels of blood glucose and improves the glucose tolerance. GPR40 agonist 5 has sufficient effectiveness for the control of hyperglycemia state in type 2 diabetic mice . GPR40 agonist 5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-13991A

(S)-CCG-1423	Ras	Metabolic Disease Cancer
(S)-CCG-1423 is an inhibitor of Rho signaling that blocks the nuclear import of MRTF-A. (S)-CCG-1423 reduces the nuclear accumulation of MRTF-A and improves glucose uptake and tolerance in insulin-resistance mice in vivo. (S)-CCG-1423 exhibits higher inhibition activity than the SR- and the R-isomers of CCG-1423 (HY-13991). (S)-CCG-1423 can be used for the research of cancer and diabetes .

HY-13991R

CCG-1423 (Standard)	Ras Apoptosis	Cancer
CCG-1423 (Standard) is the analytical standard of CCG-1423. This product is intended for research and analytical applications. CCG-1423 is an inhibitor of Rho/MRTF/SRF pathway. CCG-1423 shows activities in several cancer cells. CCG-1423 is a promising lead compound for the development of novel pharmacologic tools, and it can be used for the research of cancer and diabetes .

HY-N8518R

Malabaricone C (Standard)	Reference Standards Phospholipase p38 MAPK Apoptosis NF-κB	Metabolic Disease Inflammation/Immunology Cancer
Malabaricone C is an orally active and noncompetitive sphingomyelin synthase (SMS) inhibitor with IC50 values of 3 μM and 1.5 μM for SMS 1 and SMS 2, respectively. Malabaricone C reduces body weight gain, improves glucose tolerance, and decreases lipid accumulation in the liver, showing significant prevention of high fat diet-induced fatty liver in mice. Malabaricone C has anti-inflammatory effects, which is found in the fruits of Myristica cinnamomea King. Malabaricone C is promising for research of obesity and immunological disorders caused due to hyper-activation of T-cells .

HY-110197A

6bK formate	IDE	Metabolic Disease
6bK formate is a potent and selective insulin degrading enzyme (IDE) inhibitor with an IC₅₀ value of 50 nM. 6bK formate increases circulating insulin in high-fat-fed mice. Acute administration of 6bK formate enhances glucose tolerance to oral glucose, notably to a greater extent in high-fat-fed mice. 6bK formate can be used for type 2 diabetes research .

HY-173130

α-Glucosidase-IN-86	Glycosidase	Metabolic Disease Inflammation/Immunology
α-Glucosidase-IN-86 (Compound A4) is an orally active α-glucosidase inhibitor with an IC₅₀ of 2.72 μM. α-Glucosidase-IN-86 has high safety in mice. α-Glucosidase-IN-86 can reduce fasting blood glucose levels, improve glucose tolerance, regulate blood lipids, and has antioxidant effects in diabetic mice. α-Glucosidase-IN-86 can be used for the research of diabetes .

HY-125646

YH18968	GPR119	Metabolic Disease
YH18968 is an orally active GPR119 agonist with an EC₅₀ of 2.8 nM for inducing cAMP accumulation. YH18968 activates GPR119, elevates intracellular cyclic adenosine monophosphate levels, stimulates glucagon-like peptide-1 secretion from intestinal L cells, and triggers glucose-dependent insulin secretion from pancreatic β cells. YH18968 improves glucose tolerance in normal mice and diet-induced obese mice. YH18968 can be used for the research of type 2 diabetes .

HY-180415

UE2316	11β-HSD	Metabolic Disease
UE2316 is an orally active and specific 11βHSD1 inhibitor. UE2316 significantly improves glucose tolerance and insulin sensitivity in uremic rats. UE2316 also exacerbates hepatic fibrosis in mice. UE2316 can be used in the research of diseases such as hepatic fibrosis, uremia and diabetes mellitus .

HY-182558

Nandinine	Drug Derivative AMPK IKK NF-κB	Metabolic Disease
Nandinine is an orally active derivative of Berberine (HY-N0716). Nandinine enhances AMPK activity, inhibits the activation of IKKβ/NF-κB, and regulates the phosphorylation of IRS-1. Nandinine reverses the abnormal production of adipokines, promotes insulin-mediated glucose uptake, and alleviates insulin resistance. Nandinine improves glucose tolerance and increases the insulin sensitivity index in mice. Nandinine can be used in studies related to insulin resistance .

HY-180936

FBPase-IN-6	FBPase AMPK mTOR Ribosomal S6 Kinase (RSK)	Metabolic Disease
FBPase-IN-6 (Compound 96) is an orally active FBPase inhibitor with an IC₅₀ value of 1.769 μM. FBPase-IN-6 modulates AMPK/mTORC1/S6K signaling pathways. FBPase-IN-6 improves glucose tolerance, enhances insulin sensitivity, and promotes insulin secretion in type 2 diabetic mice .

HY-160156

SSTR5 antagonist 4	Somatostatin Receptor	Metabolic Disease
SSTR5 antagonist 4 (compound 1) is a potent, selective and orally active somatostatin subtype 5 (SSTR5) antagonist (hSSTR5 IC₅₀ = 1.3 nM, mSSTR5 IC₅₀ = 1.0 nM). SSTR5 antagonist 4 shows efficacy in mouse oral glucose tolerance test (OGTT) in high fat diet (HFD)-mice. SSTR5 antagonist 4 can be used for type 2 diabetes research .

HY-U00134A

Benzcyclane fumarate Bencyclane fumarate; Benzcyclan fumarate	5-HT Receptor	Cardiovascular Disease Neurological Disease
Benzcyclane fumarate (Bencyclane fumarate; Benzcyclan fumarate) is a serotonin receptor antagonist and a cerebral/peripheral vasodilator. Benzcyclane fumarate exerts atypical serotonin antagonistic effects in rabbit superior mesenteric arteries. Benzcyclane fumarate relaxes high K ⁺-induced contractions in rabbit basilar arteries and superior mesenteric arteries, and selectively inhibits sympathetic nerve stimulation-induced contractions in rabbit pulmonary arteries. Benzcyclane fumarate exerts non-competitive norepinephrine antagonistic effects in rabbit superior mesenteric arteries, and slightly reduces the maximum contractile response induced by histamine. Benzcyclane fumarate relaxes smooth muscles, induces transient hypotension, inhibits thrombosis, and accelerates blood fibrinolytic activity. Benzcyclane fumarate increases cerebral glucose content/uptake, enhances hypoxia tolerance in mice, and increases cerebral blood supply in dogs. Benzcyclane fumarate is applicable to studies related to cerebral vascular circulation .

HY-182905

SSTR5/TGR5-modulator-1	Somatostatin Receptor G protein-coupled Bile Acid Receptor 1	Metabolic Disease
SSTR5/TGR5-modulator-1 is an orally active and dual-target small molecule, balanced in vitro activity at human TGR5 and human SSTR5. SSTR5/TGR5-modulator-1 activates human TGR5 to promote cAMP accumulation. SSTR5/TGR5-modulator-1 blocks human SSTR5 to inhibit agonist-induced calcium mobilization. SSTR5/TGR5-modulator-1 improves glucose tolerance in mice. SSTR5/TGR5-modulator-1 alleviates gallbladder filling in mice at pharmacologically relevant doses. SSTR5/TGR5-modulator-1 has suboptimal physicochemical and metabolic properties.SSTR5/TGR5-modulator-1 can be used for the research of type 2 diabetes mellitus .

HY-U00134R

Benzcyclane (Standard) Bencyclane (Standard); Benzcyclan (Standard)	Reference Standards 5-HT Receptor	Cardiovascular Disease Neurological Disease
Benzcyclane (Standard) is the analytical standard of Benzcyclane (HY-U00134). This product is intended for research and analytical applications. Benzcyclane (Bencyclane; Benzcyclan) is a serotonin receptor antagonist and a cerebral/peripheral vasodilator. Benzcyclane exerts atypical serotonin antagonistic effects in rabbit superior mesenteric arteries. Benzcyclane relaxes high K ⁺-induced contractions in rabbit basilar arteries and superior mesenteric arteries, and selectively inhibits sympathetic nerve stimulation-induced contractions in rabbit pulmonary arteries. Benzcyclane exerts non-competitive norepinephrine antagonistic effects in rabbit superior mesenteric arteries, and slightly reduces the maximum contractile response induced by histamine. Benzcyclane relaxes smooth muscles, induces transient hypotension, inhibits thrombosis, and accelerates blood fibrinolytic activity. Benzcyclane increases cerebral glucose content/uptake, enhances hypoxia tolerance in mice, and increases cerebral blood supply in dogs. Benzcyclane is applicable to studies related to cerebral vascular circulation .

HY-182454

GPR119 agonist 4	GPR119	Metabolic Disease
GPR119 agonist 4 is a GPR119 agonist and oral glucose-lowering agent with a human GPR119 EC₅₀ of 42 nM.GPR119 agonist 4 activates GPR119.GPR119 agonist 4 reduces blood glucose area under the curve in an oral glucose tolerance test.GPR119 agonist 4 exhibits improved clearance in liver microsomes.GPR119 agonist 4 can be used for the research of type 2 diabetes mellitus .

HY-182346

FBPase-IN-7	FBPase	Metabolic Disease
FBPase-IN-7 is a fructose-1,6-bisphosphatase (FBPase) inhibitor with an IC₅₀ of 0.75 μM. FBPase-IN-7 binds to a cryptic allosteric pocket of FBPase, induces conformational rearrangement of key residues, forms a hydrogen-bond network, and disrupts substrate catalysis. FBPase-IN-7 confirms cellular stabilizes HuFBPase in hepatic cells. FBPase-IN-7 has hypoglycemic activity. FBPase-IN-7 can be used for the research of type 2 diabetes .

Cat. No.	Product Name	Target	Research Area